Analyst Ratings For Intellia Therapeutics (NASDAQ:NTLA)
Today, Cann reiterated its Hold rating on Intellia Therapeutics (NASDAQ:NTLA).
There are 2 hold ratings, 6 buy ratings on the stock.
The current consensus rating on Intellia Therapeutics (NASDAQ:NTLA) is Buy (Score: 2.75) with a consensus target price of $27.50 per share, a potential 63.30% upside.
Some recent analyst ratings include
- 8/1/2017-Cann Reiterated Rating of Hold.
- 7/22/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 7/18/2017-Oppenheimer Holdings, Inc. initiated coverage with a Market Perform rating.
- 5/15/2017-Wedbush Reiterated Rating of Outperform.
- 3/27/2017-Chardan Capital initiated coverage with a Buy rating.
- 1/5/2017-Leerink Swann Reiterated Rating of Outperform.
Recent Insider Trading Activity For Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NASDAQ:NTLA) has insider ownership of 12.80% and institutional ownership of 46.99%.
- On 7/11/2017 Venture Fund Ix L.P. Atlas, Major Shareholder, sold 150,000 with an average share price of $16.24 per share and the total transaction amounting to $2,436,000.00. View SEC Filing
- On 3/10/2017 Jean Francois Formela, Director, sold 21,132 with an average share price of $13.91 per share and the total transaction amounting to $293,946.12. View SEC Filing
- On 5/11/2016 Bros. Advisors Lp Baker, Insider, bought 200,000 with an average share price of $18.00 per share and the total transaction amounting to $3,600,000.00. View SEC Filing
- On 5/11/2016 Carl L Gordon, Director, bought 250,000 with an average share price of $18.00 per share and the total transaction amounting to $4,500,000.00. View SEC Filing
- On 5/11/2016 Institutes For Biomed Novartis, Major Shareholder, bought 277,777 with an average share price of $18.00 per share and the total transaction amounting to $4,999,986.00. View SEC Filing
Recent Trading Activity for Intellia Therapeutics (NASDAQ:NTLA)
Shares of Intellia Therapeutics closed the previous trading session at 15.94 down -0.90 -5.37% with 160,192 shares trading hands.